| no |
title |
author |
magazine |
year |
volume |
issue |
page(s) |
type |
| 1 |
Agenda science: turning nothing into something: a response to the editorial by Oldenburg et al. and its featured article by Vidal et al.
|
Kollmannsberger, C.
|
|
|
26 |
7 |
p. 1513-1514
|
article
|
| 2 |
ALK FISH rearranged and amplified tumor with negative immunohistochemistry: a rare and challenging case concerning ALK status screening in lung cancer
|
Uguen, A.
|
|
|
26 |
7 |
p. 1514-1515
|
article
|
| 3 |
Alternate sunitinib schedules in patients with metastatic renal cell carcinoma
|
Kalra, S.
|
|
|
26 |
7 |
p. 1300-1304
|
article
|
| 4 |
Alternative sunitinib schedules in metastatic renal cell carcinoma and the RAINBOW study
|
Bracarda, S.
|
|
|
26 |
7 |
p. 1512-1513
|
article
|
| 5 |
Aplidin in patients with advanced dedifferentiated liposarcomas: a French Sarcoma Group Single-Arm Phase II study
|
Toulmonde, M.
|
|
|
26 |
7 |
p. 1465-1470
|
article
|
| 6 |
A randomized phase III trial of oral S-1 plus cisplatin versus docetaxel plus cisplatin in Japanese patients with advanced non-small-cell lung cancer: TCOG0701 CATS trial
|
Kubota, K.
|
|
|
26 |
7 |
p. 1401-1408
|
article
|
| 7 |
A refined risk stratification scheme for clinical stage 1 NSGCT based on evaluation of both embryonal predominance and lymphovascular invasion
|
Lago-Hernandez, C.A.
|
|
|
26 |
7 |
p. 1396-1401
|
article
|
| 8 |
Association of proinflammatory cytokines and chemotherapy-associated cognitive impairment in breast cancer patients: a multi-centered, prospective, cohort study †
|
Cheung, Y.T.
|
|
|
26 |
7 |
p. 1446-1451
|
article
|
| 9 |
Axitinib dose titration: analyses of exposure, blood pressure and clinical response from a randomized phase II study in metastatic renal cell carcinoma
|
Rini, B.I.
|
|
|
26 |
7 |
p. 1372-1377
|
article
|
| 10 |
Benefit to neoadjuvant anti-human epidermal growth factor receptor 2 (HER2)-targeted therapies in HER2-positive primary breast cancer is independent of phosphatase and tensin homolog deleted from chromosome 10 (PTEN) status
|
Nuciforo, P.G.
|
|
|
26 |
7 |
p. 1494-1500
|
article
|
| 11 |
Biomarker testing and time to treatment decision in patients with advanced nonsmall-cell lung cancer †
|
Lim, C.
|
|
|
26 |
7 |
p. 1415-1421
|
article
|
| 12 |
Clinical usefulness of PI3K/Akt/mTOR genotyping in companion with other clinical variables in metastatic renal cell carcinoma patients treated with everolimus in the second and subsequent lines
|
Bodnar, L.
|
|
|
26 |
7 |
p. 1385-1389
|
article
|
| 13 |
Consideration of comorbidity in treatment decision making in multidisciplinary cancer team meetings: a systematic review
|
Stairmand, J.
|
|
|
26 |
7 |
p. 1325-1332
|
article
|
| 14 |
De-escalation attempts for adjuvant trastuzumab: longer beats shorter
|
Curigliano, G.
|
|
|
26 |
7 |
p. 1275-1276
|
article
|
| 15 |
Differences in attitudes and beliefs toward end-of-life care between hematologic and solid tumor oncology specialists
|
Hui, D.
|
|
|
26 |
7 |
p. 1440-1446
|
article
|
| 16 |
Different effects of the BIM deletion polymorphism on treatment of solid tumors by the tyrosine kinase inhibitors (TKI) pazopanib, sunitinib, and lapatinib
|
Spraggs, C.F.
|
|
|
26 |
7 |
p. 1515-1517
|
article
|
| 17 |
Doxorubicin plus the IGF-1R antibody cixutumumab in soft tissue sarcoma: a phase I study using the TITE-CRM model
|
Chugh, R.
|
|
|
26 |
7 |
p. 1459-1464
|
article
|
| 18 |
Duration of endocrine therapy and its impact on the results of adjuvant trials in premenopausal breast cancer patients
|
Fouad, T.M.
|
|
|
26 |
7 |
p. 1511
|
article
|
| 19 |
Editorial board
|
|
|
|
26 |
7 |
p. ii-iii
|
article
|
| 20 |
ELYPSE-7: a randomized placebo-controlled phase IIa trial with CYT107 exploring the restoration of CD4+ lymphocyte count in lymphopenic metastatic breast cancer patients
|
Trédan, O.
|
|
|
26 |
7 |
p. 1353-1362
|
article
|
| 21 |
Extreme chromosomal instability forecasts improved outcome in ER-negative breast cancer: a prospective validation cohort study from the TACT trial
|
Jamal-Hanjani, M.
|
|
|
26 |
7 |
p. 1340-1346
|
article
|
| 22 |
First-line treatment and outcome of elderly patients with primary central nervous system lymphoma (PCNSL)—a systematic review and individual patient data meta-analysis
|
Kasenda, B.
|
|
|
26 |
7 |
p. 1305-1313
|
article
|
| 23 |
FOLFIRI plus bevacizumab as second-line therapy in patients with metastatic colorectal cancer after first-line bevacizumab plus oxaliplatin-based therapy: the randomized phase III EAGLE study †
|
Iwamoto, S.
|
|
|
26 |
7 |
p. 1427-1433
|
article
|
| 24 |
Genetics of breast cancer: a topic in evolution
|
Shiovitz, S.
|
|
|
26 |
7 |
p. 1291-1299
|
article
|
| 25 |
High level of chromosomal instability in circulating tumor cells of ROS1-rearranged non-small-cell lung cancer
|
Pailler, E.
|
|
|
26 |
7 |
p. 1408-1415
|
article
|
| 26 |
High PSA anxiety and low health literacy skills: drivers of early use of salvage ADT among men with biochemically recurrent prostate cancer after radiotherapy?
|
Mahal, B.A.
|
|
|
26 |
7 |
p. 1390-1395
|
article
|
| 27 |
‘Industry corner: perspectives and controversies’: a new series in Annals of Oncology
|
Dhingra, K.
|
|
|
26 |
7 |
p. 1279
|
article
|
| 28 |
Inhibition of the phosphoinositide 3-kinase pathway for the treatment of patients with metastatic metaplastic breast cancer
|
Moulder, S.
|
|
|
26 |
7 |
p. 1346-1352
|
article
|
| 29 |
Mito-FLAG with Ara-C as bolus versus continuous infusion in recurrent or refractory AML—long-term results of a prospective randomized intergroup study of the East German Study Group Hematology/Oncology (OSHO) and the Study Alliance Leukemia (SAL) †
|
Thiel, A.
|
|
|
26 |
7 |
p. 1434-1440
|
article
|
| 30 |
PD-L1 protein expression in breast cancer is rare, enriched in basal-like tumours and associated with infiltrating lymphocytes
|
Ali, H.R.
|
|
|
26 |
7 |
p. 1488-1493
|
article
|
| 31 |
Pharmacokinetic and pharmacodynamic end points with anti-VEGFR: the more it hurts, the more it works?
|
Mir, O.
|
|
|
26 |
7 |
p. 1277-1278
|
article
|
| 32 |
Phase I dose-escalating trial of Escherichia coli purine nucleoside phosphorylase and fludarabine gene therapy for advanced solid tumors †
|
Rosenthal, E.L.
|
|
|
26 |
7 |
p. 1481-1487
|
article
|
| 33 |
Phase II trial of everolimus and erlotinib in patients with platinum-resistant recurrent and/or metastatic head and neck squamous cell carcinoma
|
Massarelli, E.
|
|
|
26 |
7 |
p. 1476-1480
|
article
|
| 34 |
Plasma vemurafenib concentrations in advanced BRAFV600mut melanoma patients: impact on tumour response and tolerance †
|
Funck-Brentano, E.
|
|
|
26 |
7 |
p. 1470-1475
|
article
|
| 35 |
Profiling cancer gene mutations in longitudinal epithelial ovarian cancer biopsies by targeted next-generation sequencing: a retrospective study
|
Beltrame, L.
|
|
|
26 |
7 |
p. 1363-1371
|
article
|
| 36 |
Prognostic value of tumor-infiltrating lymphocytes on residual disease after primary chemotherapy for triple-negative breast cancer: a retrospective multicenter study
|
Dieci, M.V.
|
|
|
26 |
7 |
p. 1518
|
article
|
| 37 |
Recommendations for standardized pathological characterization of residual disease for neoadjuvant clinical trials of breast cancer by the BIG-NABCG collaboration
|
Bossuyt, V.
|
|
|
26 |
7 |
p. 1280-1291
|
article
|
| 38 |
RECORD-2: phase II randomized study of everolimus and bevacizumab versus interferon α-2a and bevacizumab as first-line therapy in patients with metastatic renal cell carcinoma
|
Ravaud, A.
|
|
|
26 |
7 |
p. 1378-1384
|
article
|
| 39 |
Six versus 12 months of adjuvant trastuzumab in combination with dose-dense chemotherapy for women with HER2-positive breast cancer: a multicenter randomized study by the Hellenic Oncology Research Group (HORG)
|
Mavroudis, D.
|
|
|
26 |
7 |
p. 1333-1340
|
article
|
| 40 |
Sunitinib 2 weeks on, 1 off: strengths and weaknesses
|
Iacovelli, R.
|
|
|
26 |
7 |
p. 1511-1512
|
article
|
| 41 |
Table of Contents
|
|
|
|
26 |
7 |
p. iv-vi
|
article
|
| 42 |
Targeting HER2 aberrations as actionable drivers in lung cancers: phase II trial of the pan-HER tyrosine kinase inhibitor dacomitinib in patients with HER2-mutant or amplified tumors
|
Kris, M.G.
|
|
|
26 |
7 |
p. 1421-1427
|
article
|
| 43 |
The effect of filgrastim or pegfilgrastim on survival outcomes of patients with cancer receiving myelosuppressive chemotherapy
|
Lyman, G.H.
|
|
|
26 |
7 |
p. 1452-1458
|
article
|
| 44 |
The potential for epigenetic analysis of paediatric CNS tumours to improve diagnosis, treatment and prognosis
|
Sexton-Oates, A.
|
|
|
26 |
7 |
p. 1314-1324
|
article
|
| 45 |
Titration of signalling output: insights into clinical combinations of MEK and AKT inhibitors
|
Stewart, A.
|
|
|
26 |
7 |
p. 1504-1510
|
article
|
| 46 |
Variation in transplacental transfer of tyrosine kinase inhibitors in the human perfused cotyledon model
|
Jovelet, C.
|
|
|
26 |
7 |
p. 1500-1504
|
article
|
Journal description